Reed Smith and Lindahl among firms advising on Meda’s £1.8bn acquisition of Rottapharm
Reed Smith has advised alongside a raft of European firms on Swedish pharmaceuticals company Meda’s acquisition of its Italian rival Rottapharm for £1.8bn. The transaction followed a cancelled IPO by Rottapharm, which failed to achieve the valuation sought by its owner, the Rovati family. Reed Smith advised longstanding client Meda on the transaction, led by […]